Industry landscapes
The companies, capital and talent shaping life sciences in New York City. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
56 of 811 tracked companies have open roles.
394 of 811 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 867 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 10.1% of disclosed capital, while 51.4% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $598.87M | 44 | 60 |
| 2017 | $1.11B | 59 | 59 |
| 2018 | $859.65M | 58 | 65 |
| 2019 | $1.78B | 56 | 67 |
| 2020 | $1.89B | 57 | 78 |
| 2021 | $3.28B | 39 | 79 |
| 2022 | $2.01B | 33 | 67 |
| 2023 | $1.03B | 26 | 74 |
| 2024 | $2.12B | 18 | 70 |
| 2025 | $1.23B | 9 | 55 |
Share of all disclosed company funding.
975 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Healthier Capital and Primary Venture Partner and others.
Backed by Draper and SOSV and others.
Backed by .
Backed by Global Innovation Fund.
Backed by Satori Capital and Prime Movers Lab.
Backed by RTW Investments.
Backed by .
Backed by .
Backed by Novo Holdings and Silver Lake and others.
Backed by Andreessen Horowitz and Sanofi and others.
Backed by Nordic Capital.
Backed by Arch Venture Partners and F-Prime Capital and others.
Backed by EDBI and Pavilion Capital Partners and others.
Backed by Janchor Partners and RA Capital Management and others.
Backed by Leaps by Bayer and Casdin Capital and others.
Backed by Lux Capital and Mubadala and others.
Backed by Tiger Global Management and Casdin Capital and others.
Backed by Wellington and Venrock and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 21 reporting entities from 60 eligible matches.
Sum of reporting-entity revenue; not New York City market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
6 of 21 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 21 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Axsome Therapeutics ↗1579428 | $638.5m | $-183.2m | -28.7% | — | — |
| TG Therapeutics ↗1001316 | $616.3m | $447.2m | +72.6% | — | — |
| SIGA Technologies ↗1010086 | $94.6m | $23.3m | +24.6% | — | — |
| Delcath ↗872912 | $85.2m | $2.7m | +3.2% | — | — |
| Recursion Pharmaceuticals ↗1601830 | $74.7m | $-644.8m | -863.4% | — | — |
| Fortress Biotech ↗1429260 | $61.2m | $6.8m | +11.1% | — | — |
| Tonix Pharma ↗1430306 | $13.1m | $-124.0m | -946.2% | — | — |
| Schrodinger ↗1490978 | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the New York City companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
6 of the 811 companies on this page carry a measured traffic record (0.7%); these are the largest of those, by monthly visits. The median among them is 781,111 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Hungryroothungryroot.com | 2,941,106 | 50 | 88.6% |
| Noomnoom.com | 1,939,011 | 54 | 86.8% |
| Nutrafolnutrafol.com | 938,039 | 54 | 77.3% |
| Nanitnanit.com | 624,183 | 46 | 81.7% |
| TrialXtrialx.com | 138,961 | 32 | 86.7% |
| NOVOSnovoslabs.com | 131,715 | 42 | 71.8% |
Visits and authority are third-party web estimates, not company-reported figures.
20 of these companies (2.5%) publish at least one Android app — 28 apps in all, carrying 23.7M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Noom: Weight Loss & GLP-1 CareNoom | 22.8M | 4.1 | Health & Fitness |
| NanitNanit | 501.7K | 3.9 | Parenting |
| Hungryroot: Healthy GroceriesHungryroot | 176K | 4.7 | Food & Drink |
| i-BelongBelong | 38.3K | 4.1 | Social |
| Genoplan\'s Genetic AnalysisGenoplan | 27.4K | — | Health & Fitness |
| WeightMate.AI For Weight LossBelong | 27K | 4.3 | Health & Fitness |
| psVerify MobilePharmaSecure | 23.8K | — | Medical |
| Nanit Sound and LightNanit | 22.5K | 3.5 | Parenting |
| SYNERGY-AI Cancer Trial FinderMassive Bio | 22.3K | 4.8 | Medical |
| BelongAI Dave - Cancer MentorBelong | 21.2K | 4.4 | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Nutraceuticals Tech | 5 | 23M | Noom: Weight Loss & GLP-1 Care 22.8M | |
| Employee Health It | 2 | 22.8M | Newtopia 19.4K | |
| Wearable Technology | 7 | 534.2K | Nanit 501.7K | |
| Disease Self Management | 6 | 533.6K | Nanit Sound and Light 22.5K | |
| Online Mom & Baby Care | 4 | 524.8K | Nanit Beta 554 | |
| Life Sciences Tech | 10 | 140.4K | i-Belong 38.3K | |
| Healthcare It | 5 | 88.3K | WeightMate.AI For Weight Loss 27K | |
| Online Health Information | 4 | 87K | BelongAI Dave - Cancer Mentor 21.2K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 27 of 28 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
44 companies hiring · $17.82B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Candid is choosing the M&A route instead, opting to accept a $2 billion buyout offer that gives UCB the biotech’s pipeline of T cell engagers for immune disorders.
Lucid Diagnostics on Thursday announced that it had priced an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share for total expected gross proceeds of $18 million.
Recursion, based in Salt Lake City, prefers to call itself a “TechBio” company—… went public in 2021 with a $436.4 million raise...
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).
The gross proceeds to the Company from the offering were approximately $2.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital.
Horizon Technology Finance Corporation announced it has provided a $40 million loan facility to Hyperfine, Inc., with an initial $15 million funded at closing and up to $25 million available for future growth.
Deals included a $2.7 billion financing for cloud services platform Dropbox and $570 million for Axsome Therapeutics.
Pfizer’s fight with Novo Nordisk to buy obesity drug start-up Metsera
One of the standout healthtech deals was Esper Bionics, which secured $5 million in a round led by YZR Capital.
Epicured, a food-is-medicine meal delivery company originally focused on digestive health, has acquired Chiyo, a women’s nutrition company offering stage-specific meal programs spanning cycle support, fertility, pregnancy, postpartum, and beyond.
Top 10 categories among 1,074 recorded events in the 24-month window.
35 companies with recorded IPO activity
IPO · NASDAQ2 reports
IPO · NASDAQ Global Market8 reports
IPO · Nasdaq Global Market5 reports
IPO · Nasdaq1 reports
OFS · Nasdaq1 reports
IPO1 reports
Follow-on Offering · Nasdaq1 reports
Follow-on Offering · NASDAQ1 reports
40 tracked people moves
Departure Strategic Advisor
Departure Previously Board Member
Departure Previously Board Member
Appointment Chief Product & Technology Officer
Appointment President and Chief Financial Officer
Appointment Chief Commercial Officer
Appointment Chief Financial Officer
Appointment Senior Vice President and Chief Business Officer, Medical Devices
Products, platforms and features in the recorded window
6 recorded customer wins
Customer: U.S. Department of Veterans AffairsHealthcare
Customer: reviveRegenerative Medicine
Customer: U.S. Dept of Veterans Affairs
Customer: Healthcare
Customer: gilead sciences
Customer: hitachi chemicalBiotechnology
9 companies with reported reductions
78 rolesIPO market downturn
146 roles
20.0% rolescost reduction
Scale not stated rolescash runway
80 rolesstrategic realignment
70.0% rolesinvestment pressure
34 recorded events
approved for uplistingNasdaq
approved for grantNasdaq
approved for saleU.S. Food & Drug Administration
approved for sale
14 tracked suits
takeover disputeCivil · Filed
temporary restraining order to block Novo’s interference and force Metsera to abide by itsAntitrust · Filed
Reported company results in the recorded window.
Median across 115 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| UCB S.A.→Candid ↗ | Announced | 2026-05-05 | $2.0B |
| sun pharmaceutical industries→Checkpoint Therapeutics ↗ | Announced | 2026-04-27 | $355.0M |
| Everest Medicines→Hasten Biopharmaceuticals (Asia) | Announced | 2026-04-09 | $250.0M |
| johnson & johnson→Intra-Cellular Therapies ↗ | Completed | 2026-03-09 | $14.6B |
| ARK Invest→Recursion Pharmaceuticals ↗ | Announced | 2026-02-27 | Not stated in snapshot |
| Pfizer and Novo Nordisk→Metsera ↗ | Announced | 2026-02-26 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
1,034 postings in the preceding 12 months. The full 3,068-posting snapshot covers 67 employers.
28 tracked postings mention remote work.
559 postings specify a level.
Top skills across 3,068 tracked postings in the available jobs snapshot.
Median across 300 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| Noom ↗ | 644 |
| Axsome Therapeutics ↗ | 545 |
| Candid ↗ | 501 |
| H1 ↗ | 480 |
| Recursion Pharmaceuticals ↗ | 400 |
| Everest Medicines ↗ | 395 |
| MeiraGTx ↗ | 358 |
| Synergy Pharmaceuticals ↗ | 313 |
623 founders and chief executives across 436 companies.
Merck, Washington University School of Medicine in St. Louis, 1990
Ex-Co-Founder WorkSmart Labs, Google. Princeton University AB 2004.
Versanis Bio, ex-National Geographic, Founder Tigris Pharmaceuticals, Co-Founder Apple Tree Partners. McGill University BA 1989…
Founder Foundation 649, ex-Co-Founder Day 7 Photography, Oscar Insurance, salesforce.com. The University of Texas at Austin BSc 2013
Ex- CEO 4SC. University of Würzburg PhD 1997
Ex- McKinsey. Harvard University AB 2000, Harvard Kennedy School MPA 2005
Kallyope, ex-Inheris Biopharma, ex-G And W Laboratories, Harvard Business School, 2007
Ex-Moderna Therapeutics, Alexion Pharmaceuticals, Morgan Stanley, Credit Suisse. McGill University, Columbia University JD
Ex-Pfizer, Lehman Brothers. University of Pennsylvania BA, Harvard Business School MBA
Co-Founder & CEO ResearchConnection.
Ex-Adare Pharmaceuticals, McNeil Specialty Products, Lazarus Pharmaceuticals. St. Joseph’s University
Ex-Everest Medicines, CBC Group, Lao K Consulting, Innovent Biologics. Indiana University Bloomington BS 1977…
153 profiles with education records.
22 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
4,380 articles in the measured 12-month window.
Life Sciences coverage tagged New York City · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 1,268 |
| 2021Q3 | 1,604 |
| 2021Q4 | 1,350 |
| 2022Q1 | 1,277 |
| 2022Q2 | 1,167 |
| 2022Q3 | 1,271 |
| 2022Q4 | 998 |
| 2023Q1 | 1,039 |
| 2023Q2 | 1,300 |
| 2023Q3 | 1,148 |
| 2023Q4 | 1,347 |
| 2024Q1 | 1,510 |
| 2024Q2 | 1,419 |
| 2024Q3 | 1,298 |
| 2024Q4 | 1,108 |
| 2025Q1 | 1,873 |
| 2025Q2 | 972 |
| 2025Q3 | 1,339 |
| 2025Q4 | 1,031 |
| 2026Q1 | 1,035 |
Article volume measures coverage, not market sales.
1,606 recorded company events across 127 companies; percentages use that event total.
Life Sciences coverage tagged New York City · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 3,157 | 898 | 252% |
| vaccine trials | 2,962 | 904 | 228% |
| vaccination campaigns | 2,752 | 555 | 396% |
| vaccine immunogenicity | 2,473 | 668 | 270% |
| mass vaccination sites | 2,021 | 272 | 643% |
| vaccination coverage | 1,516 | 202 | 650% |
| vaccine effectiveness study | 1,400 | 251 | 458% |
| angel investors | 1,344 | 590 | 128% |
| covid-19 vaccine development | 1,335 | 238 | 461% |
| pandemic vaccine stockpiling | 1,294 | 242 | 435% |
| investigational new vaccine | 451 | 1,069 | -58% |
| cell-based therapies | 619 | 1,059 | -42% |
| viral vector vaccines | 684 | 1,048 | -35% |
| cancer biomarkers | 670 | 1,040 | -36% |
| diagnostic biotechnology | 570 | 948 | -40% |
United States comparison coverage
core inflation rate, inflation outlook, inflation breakdown
52.8% critical · 34.6% positiveangel investors, vaccine candidates, vaccine trials
49.1% critical · 55.2% positivegdp acceleration, gdp growth rate, economic output growth
49.7% critical · 39.6% positiveLife Sciences coverage tagged New York City. Topic labels describe recorded classifications and can include broad context.
6,260 papers in the recorded india scope.
Tone counts: 5,526 positive · 456 neutral · 278 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro
Common problems researchers identify · 0118.4% of this theme group
Researchers highlight technical hurdles in synthetic biology, enzymatic processes, and nanotech for scalable bioproducts.
Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)
Microbial Enzymes: Tools for Biotechnological Processes
Medical biofilms
| Year | Share index |
|---|---|
| 2022 | 67.9 |
| 2023 | 70.3 |
| 2024 | 84.4 |
| 2025 | 67.1 |
Common problems researchers identify · 0215.7% of this theme group
Papers flag contamination and outbreak concerns linking produce safety and public health.
Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)
The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities
A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments
| Year | Share index |
|---|---|
| 2022 | 301.0 |
| 2023 | 265.8 |
| 2024 | 276.2 |
| 2025 | 304.0 |
Common problems researchers identify · 0315.5% of this theme group
Studies discuss mutation detection, DNA methylation profiling, and metabolic alterations in tumors.
Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine
| Year | Share index |
|---|---|
| 2022 | 974.1 |
| 2023 | 1199.2 |
| 2024 | 866.8 |
| 2025 | 797.1 |
Common problems researchers identify · 0415.2% of this theme group
Works examine genetic engineering and hormone pathways to improve crop resilience to environmental stress.
Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)
Genetic Engineering for Modern Agriculture: Challenges and Perspectives
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 1472.5 |
| 2023 | 1503.8 |
| 2024 | 1656.9 |
| 2025 | 1839.0 |
Common problems researchers identify · 0514.7% of this theme group
Research points to limited micronutrient production and the need for better biofortification methods.
Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)
Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016
Food fermentations: Microorganisms with technological beneficial use
| Year | Share index |
|---|---|
| 2022 | 120.6 |
| 2023 | 117.1 |
| 2024 | 113.1 |
| 2025 | 122.2 |
Common problems researchers identify · 0611.1% of this theme group
Authors describe mechanisms and global impact of resistant bacteria on treatment effectiveness.
Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)
An overview of the antimicrobial resistance mechanisms of bacteria
The global threat of antimicrobial resistance: science for intervention
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.5% of this theme group
Papers address rising resistance in vectors and the challenges for integrated control strategies.
Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)
Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
| Year | Share index |
|---|---|
| 2022 | 3.4 |
| 2023 | 3.1 |
| 2024 | 4.4 |
| 2025 | 4.3 |
Cautions · 0124.6% of this theme group
Studies caution about incomplete understanding of repair pathways and mutation consequences.
DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)
Examining the link between chromosomal instability and aneuploidy in human cells
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
| Year | Share index |
|---|---|
| 2022 | 101.2 |
| 2023 | 139.0 |
| 2024 | 91.9 |
| 2025 | 79.2 |
Cautions · 0218.1% of this theme group
Research warns of unintended immune effects from antibodies and cell‑based interventions.
Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data
| Year | Share index |
|---|---|
| 2022 | 543.7 |
| 2023 | 602.0 |
| 2024 | 448.8 |
| 2025 | 441.1 |
Cautions · 0314.4% of this theme group
Works highlight potential hazards of new ingredients, nanomaterials, and sugar‑related health impacts.
Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption
| Year | Share index |
|---|---|
| 2022 | 122.8 |
| 2023 | 120.4 |
| 2024 | 118.6 |
| 2025 | 154.1 |
Cautions · 0411.6% of this theme group
Papers note uncertainties in feed additives affecting animal health and greenhouse gas emissions.
Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)
Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis
The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst
| Year | Share index |
|---|---|
| 2022 | 126.8 |
| 2023 | 122.4 |
| 2024 | 118.5 |
| 2025 | 129.2 |
Cautions · 0510.8% of this theme group
Authors discuss practical challenges and trait prediction accuracy in breeding programs.
Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2367.9 |
| 2023 | 2351.5 |
| 2024 | 2081.1 |
| 2025 | 1566.0 |
Cautions · 0610.5% of this theme group
Research cautions about efficacy and ecological impact of biological control and pesticide use.
PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)
The use of fungal entomopathogens as endophytes in biological control: a review
Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?
| Year | Share index |
|---|---|
| 2022 | 1443.5 |
| 2023 | 1484.3 |
| 2024 | 1642.9 |
| 2025 | 1827.1 |
Cautions · 079.9% of this theme group
Studies warn of cross‑species resistance development linked to veterinary antibiotic practices.
Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)
Multidrug evolutionary strategies to reverse antibiotic resistance
Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Opportunities · 0119.6% of this theme group
Papers explore microbial products for health improvement and disease prevention.
Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)
Probiotics, their health benefits and applications for developing healthier foods: a review
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 2406.7 |
| 2023 | 2240.7 |
| 2024 | 2316.1 |
| 2025 | 1955.8 |
Opportunities · 0219.3% of this theme group
Research identifies knockdown and pathway modulation strategies for therapeutic development.
Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)
PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development
Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0313.2% of this theme group
Works focus on engineered T cells, antigen targeting, and tumor‑microenvironment interactions.
Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
| Year | Share index |
|---|---|
| 2022 | 289.3 |
| 2023 | 336.1 |
| 2024 | 224.8 |
| 2025 | 204.1 |
Opportunities · 0412.8% of this theme group
Studies present new approaches to modify methylation and enhance genome stability.
DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition
| Year | Share index |
|---|---|
| 2022 | 224.2 |
| 2023 | 281.6 |
| 2024 | 196.5 |
| 2025 | 158.4 |
Opportunities · 0512.2% of this theme group
Papers describe fluorescent and magnetic nanoparticle probes for real‑time disease visualization.
In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl
| Year | Share index |
|---|---|
| 2022 | 480.4 |
| 2023 | 520.5 |
| 2024 | 397.5 |
| 2025 | 406.8 |
Opportunities · 0611.7% of this theme group
Research leverages sequencing and germplasm selection to accelerate breeding of resilient varieties.
Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)
Genotyping‐by‐Sequencing for Plant Breeding and Genetics
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 56.0 |
| 2023 | 51.4 |
| 2024 | 46.1 |
| 2025 | 53.1 |
Opportunities · 0711.3% of this theme group
Works investigate mRNA methylation and microRNA pathways for controlling gene expression.
Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)
m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc
| Year | Share index |
|---|---|
| 2022 | 229.2 |
| 2023 | 195.8 |
| 2024 | 157.3 |
| 2025 | 136.5 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 32.6% | 26.0% |
| Promising | 31.0% | 37.4% |
| Descriptive | 17.5% | 17.6% |
| Problem-identifying | 9.1% | 9.7% |
| Cautionary | 5.8% | 4.5% |
| Comparative | 2.8% | 3.8% |
| Critical | 1.3% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 18 | 0.3% | 2 (11.1%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 4 | 0.07% | 1 (25.0%) | 0.15% |
| Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis | 3 | 0.05% | 1 (33.3%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 1 | 0.02% | 1 (100.0%) | 0.01% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Compare demand signals in New York City’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Maternal & child health ↗Disease Burden | 92.9 | 0.0 | +92.9 | +32.8% | |
| Infectious outbreaks ↗Disease Burden | 64.3 | 30.0 | +34.3 | +5.7% | |
| Layoffs & income shocks ↗Spending Pressure | 85.7 | 60.0 | +25.7 | +20.6% | |
| Air pollution ↗Environmental Driver | 28.6 | 30.0 | -1.4 | -1.6% | |
| Cancer burden ↗Disease Burden | 35.7 | 80.0 | -44.3 | -10.3% | |
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 42.9 | 100.0 | -57.1 | +23.7% | |
| Mental health ↗Disease Burden | 35.7 | — | No matching category | — | -15.9% |
| Ageing & elder care ↗Disease Burden | 14.3 | — | No matching category | — | -23.4% |
Showing all 8 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. New York City is highlighted.
Each city’s reading is a share of its own coverage. Rows cover all of the United States for this page's signal families; New York City is marked.
Layoffs & income shocks · Maternal & child health · Cancer burden
Layoffs & income shocks · Mental health · Maternal & child health
Infectious outbreaks · Layoffs & income shocks · Air pollution
Layoffs & income shocks · Maternal & child health · Air pollution
Layoffs & income shocks · Mental health · Maternal & child health
Maternal & child health · Layoffs & income shocks · Mental health
Maternal & child health · Mental health · Air pollution
Maternal & child health · Mental health · Layoffs & income shocks
Maternal & child health · Cancer burden · Mental health
Layoffs & income shocks · Maternal & child health · Mental health
Cancer burden · Maternal & child health · Diabetes, hypertension & cardiac burden
Layoffs & income shocks · Maternal & child health · Mental health
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 30 | 3.77 |
| 2024Q4 | 52 | 6.27 |
| 2025Q1 | 97 | 9.68 |
| 2025Q2 | 68 | 7.8 |
| 2025Q3 | 298 | 12.1 |
| 2025Q4 | 40 | 4.8 |
| 2026Q1 | 47 | 5.29 |
Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 91 | 11.45 |
| 2024Q4 | 26 | 3.14 |
| 2025Q1 | 41 | 4.09 |
| 2025Q2 | 105 | 12.04 |
| 2025Q3 | 172 | 6.98 |
| 2025Q4 | 36 | 4.32 |
| 2026Q1 | 23 | 2.59 |
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 123 | 15.47 |
| 2024Q4 | 163 | 19.67 |
| 2025Q1 | 197 | 19.66 |
| 2025Q2 | 126 | 14.45 |
| 2025Q3 | 394 | 16.0 |
| 2025Q4 | 283 | 33.97 |
| 2026Q1 | 179 | 20.14 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 25 | 3.14 |
| 2024Q4 | 27 | 3.26 |
| 2025Q1 | 22 | 2.2 |
| 2025Q2 | 46 | 5.28 |
| 2025Q3 | 81 | 3.29 |
| 2025Q4 | 20 | 2.4 |
| 2026Q1 | 31 | 3.49 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 31 | 3.9 |
| 2024Q4 | 63 | 7.6 |
| 2025Q1 | 65 | 6.49 |
| 2025Q2 | 48 | 5.51 |
| 2025Q3 | 59 | 2.4 |
| 2025Q4 | 51 | 6.12 |
| 2026Q1 | 65 | 7.31 |
Chronic cardiometabolic burden can turn into decades of management demand per patient.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 18 | 2.26 |
| 2024Q4 | 23 | 2.77 |
| 2025Q1 | 31 | 3.09 |
| 2025Q2 | 37 | 4.24 |
| 2025Q3 | 62 | 2.52 |
| 2025Q4 | 37 | 4.44 |
| 2026Q1 | 24 | 2.7 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 66 | 8.3 |
| 2024Q4 | 87 | 10.5 |
| 2025Q1 | 38 | 3.79 |
| 2025Q2 | 46 | 5.28 |
| 2025Q3 | 160 | 6.5 |
| 2025Q4 | 56 | 6.72 |
| 2026Q1 | 54 | 6.08 |
An ageing base can shift demand toward geriatric, home and chronic care.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 40 | 5.03 |
| 2024Q4 | 35 | 4.22 |
| 2025Q1 | 44 | 4.39 |
| 2025Q2 | 35 | 4.01 |
| 2025Q3 | 61 | 2.48 |
| 2025Q4 | 35 | 4.2 |
| 2026Q1 | 49 | 5.51 |
New York City life sciences coverage
JAMA
9,847 citations in the snapshot
BMJ
2,939 citations in the snapshot
JAMA
1,226 citations in the snapshot
JAMA
835 citations in the snapshot
New York City coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| vaccine storage training | 73 | 21 | 142.3% |
| immunization competency | 50 | 16 | 117.8% |
| covid-19 fatalities | 69 | 26 | 85.0% |
| health crisis tolls | 23 | 9 | 78.1% |
| smallpox vaccination | 20 | 8 | 74.3% |
| healthy diet cancer | 50 | 21 | 66.0% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 1 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗